Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Friday, up 5.10% from the previous trading day, before settling in for the closing price of $4.90. Over the past 52 weeks, AMLX has traded in a range of $1.58-$7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 127.75%. While this was happening, its average annual earnings per share was recorded 60.55%. With a float of $65.31 million, this company’s outstanding shares have now reached $89.08 million.
Let’s determine the extent of company efficiency that accounts for 123 employees. In terms of profitability, gross margin is 775.71%, operating margin of 16317.06%, and the pretax margin is 17255.66%.
Amylyx Pharmaceuticals Inc (AMLX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 26.74%, while institutional ownership is 76.20%. The most recent insider transaction that took place on Mar 31 ’25, was worth 37,806. In this transaction Chief Financial Officer of this company sold 10,896 shares at a rate of $3.47, taking the stock ownership to the 290,988 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Medical Officer sold 12,425 for $3.47, making the entire transaction worth $43,082. This insider now owns 194,375 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 60.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.31% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 12.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.34 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 0.89 million, which is a drop from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 45.57%. Additionally, its Average True Range was 0.40.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 86.44%, which indicates a significant increase from 70.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.06% in the past 14 days, which was lower than the 81.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.41, while its 200-day Moving Average is $3.95. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $5.42. Second resistance stands at $5.69. The third major resistance level sits at $6.04. If the price goes on to break the first support level at $4.79, it is likely to go to the next support level at $4.44. Now, if the price goes above the second support level, the third support stands at $4.17.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 459.08 million has total of 89,141K Shares Outstanding. Its annual sales at the moment are 87,370 K in contrast with the sum of -301,740 K annual income. Company’s last quarter sales were recorded -660 K and last quarter income was -37,550 K.
